Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in Nat Rev Clin Oncol

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    July 2021
  1. NAROD SA
    Adjuvant olaparib - should all patients with breast cancer have genetic testing?
    Nat Rev Clin Oncol. 2021 Jul 19. pii: 10.1038/s41571-021-00544.
    PubMed    


    March 2021
  2. GYAWALI B, Kesselheim AS
    FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Nat Rev Clin Oncol. 2021 Mar 25. pii: 10.1038/s41571-021-00504.
    PubMed    


    February 2021
  3. PALUCH-SHIMON S, Cardoso F
    PARP inhibitors coming of age.
    Nat Rev Clin Oncol. 2021;18:69-70.
    PubMed    


    January 2021
  4. VAIDYA JS, Bulsara M, Baum M, Alvarado M, et al
    Intraoperative radiotherapy for breast cancer: powerful evidence to change practice.
    Nat Rev Clin Oncol. 2021 Jan 25. pii: 10.1038/s41571-021-00471.
    PubMed    


  5. SASIENI PD, Sawyer EJ
    Reply to 'Intraoperative radiotherapy for breast cancer: powerful evidence to change practice'.
    Nat Rev Clin Oncol. 2021 Jan 25. pii: 10.1038/s41571-021-00472.
    PubMed    


    December 2020
  6. SIDAWAY P
    Neoadjuvant therapy improves pCR rate.
    Nat Rev Clin Oncol. 2020;17:718.
    PubMed    


    November 2020
  7. CURIGLIANO G
    CDK4/6 inhibitors for HR(+)HER2(-) early stage breast cancer - when to escalate treatment?
    Nat Rev Clin Oncol. 2020 Nov 24. pii: 10.1038/s41571-020-00453.
    PubMed    


    October 2020
  8. SASIENI PD, Sawyer EJ
    Intraoperative radiotherapy for early breast cancer - insufficient evidence to change practice.
    Nat Rev Clin Oncol. 2020 Oct 21. pii: 10.1038/s41571-020-00444.
    PubMed    


    July 2020
  9. ROMERO D
    Myocardial infarction promotes breast cancer recurrence.
    Nat Rev Clin Oncol. 2020 Jul 24. pii: 10.1038/s41571-020-0418.
    PubMed    


    June 2020
  10. PASHAYAN N, Antoniou AC, Ivanus U, Esserman LJ, et al
    Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Nat Rev Clin Oncol. 2020 Jun 29. pii: 10.1038/s41571-020-0412.
    PubMed     Abstract available


  11. PASHAYAN N, Antoniou AC, Ivanus U, Esserman LJ, et al
    Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Nat Rev Clin Oncol. 2020 Jun 18. pii: 10.1038/s41571-020-0388.
    PubMed     Abstract available


  12. NAGAR H, Formenti SC
    Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy.
    Nat Rev Clin Oncol. 2020;17:332-334.
    PubMed    


  13. SCARANTI M, Cojocaru E, Banerjee S, Banerji U, et al
    Exploiting the folate receptor alpha in oncology.
    Nat Rev Clin Oncol. 2020;17:349-359.
    PubMed     Abstract available


    April 2020
  14. KILLOCK D
    Moving pembrolizumab forwards.
    Nat Rev Clin Oncol. 2020;17:196.
    PubMed    


    March 2020
  15. SHIEH Y, Ziv E, Kerlikowske K
    Interval breast cancers - insights into a complex phenotype.
    Nat Rev Clin Oncol. 2020;17:138-139.
    PubMed    


  16. KILLOCK D
    AI outperforms radiologists in mammographic screening.
    Nat Rev Clin Oncol. 2020;17:134.
    PubMed    


  17. SIDAWAY P
    HER2-targeted agents overcome resistance.
    Nat Rev Clin Oncol. 2020;17:133.
    PubMed    


    February 2020
  18. BYRNE A, Savas P, Sant S, Li R, et al
    Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
    Nat Rev Clin Oncol. 2020 Feb 28. pii: 10.1038/s41571-020-0333.
    PubMed     Abstract available


    December 2019
  19. GOUTSOULIAK K, Veeraraghavan J, Sethunath V, De Angelis C, et al
    Towards personalized treatment for early stage HER2-positive breast cancer.
    Nat Rev Clin Oncol. 2019 Dec 13. pii: 10.1038/s41571-019-0299.
    PubMed     Abstract available


  20. KILLOCK D
    CDK4/6 inhibitors prolong OS.
    Nat Rev Clin Oncol. 2019;16:722.
    PubMed    


    November 2019
  21. PONDE N, de Azambuja E
    PERSEPHONE - implications for clinical practice in 2019.
    Nat Rev Clin Oncol. 2019;16:663-664.
    PubMed    


    October 2019
  22. KILLOCK D
    Personalized MRD assays and therapy?
    Nat Rev Clin Oncol. 2019;16:593.
    PubMed    


    September 2019
  23. OH DY, Bang YJ
    HER2-targeted therapies - a role beyond breast cancer.
    Nat Rev Clin Oncol. 2019 Sep 23. pii: 10.1038/s41571-019-0268.
    PubMed     Abstract available


    August 2019
  24. SIDAWAY P
    Alpelisib effective in advanced-stage disease.
    Nat Rev Clin Oncol. 2019;16:466.
    PubMed    


  25. KILLOCK D
    Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC.
    Nat Rev Clin Oncol. 2019;16:464.
    PubMed    


  26. ROMERO D
    HDAC inhibitors tested in phase III trial.
    Nat Rev Clin Oncol. 2019;16:465.
    PubMed    


    June 2019
  27. SIDAWAY P
    Fulvestrant enables better outcomes.
    Nat Rev Clin Oncol. 2019;16:337.
    PubMed    


  28. BRADLEY CA
    Brain metastases respond to neratinib plus capecitabine.
    Nat Rev Clin Oncol. 2019;16:336.
    PubMed    


    May 2019
  29. CUZICK J
    Predicting late recurrence in ER-positive breast cancer.
    Nat Rev Clin Oncol. 2019 May 15. pii: 10.1038/s41571-019-0228.
    PubMed    


  30. D'ABREO N, Adams S
    Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    Nat Rev Clin Oncol. 2019 May 3. pii: 10.1038/s41571-019-0216.
    PubMed    


  31. ROMERO D
    Healthier bones and less recurrence with denosumab.
    Nat Rev Clin Oncol. 2019;16:272.
    PubMed    


    April 2019
  32. SIDAWAY P
    Early PET response predicts complete response.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed    


  33. KILLOCK D
    CTCs 'piggyback' off neutrophils.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed    


    December 2018
  34. RICHMAN J, Dowsett M
    Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
    Nat Rev Clin Oncol. 2018 Dec 18. pii: 10.1038/s41571-018-0145.
    PubMed     Abstract available


    September 2018
  35. PONDE NF, Zardavas D, Piccart M
    Progress in adjuvant systemic therapy for breast cancer.
    Nat Rev Clin Oncol. 2018 Sep 11. pii: 10.1038/s41571-018-0089.
    PubMed     Abstract available


    June 2018
  36. SIDAWAY P
    Ribociclib effective in HR(+), HER2(-) breast cancer.
    Nat Rev Clin Oncol. 2018 Jun 21. pii: 10.1038/s41571-018-0059.
    PubMed    


    March 2018
  37. SIDAWAY P
    Breast cancer: Changes in clonal dynamics predict response to palbociclib.
    Nat Rev Clin Oncol. 2018 Mar 20. pii: nrclinonc.2018.
    PubMed    


  38. SIDAWAY P
    Breast cancer: Fibroblast subtypes alter the microenvironment.
    Nat Rev Clin Oncol. 2018 Mar 6. pii: nrclinonc.2018.
    PubMed    


    February 2018
  39. ROMERO D
    Breast cancer: Metronomic chemotherapy for elderly and/or frail patients.
    Nat Rev Clin Oncol. 2018 Feb 27. pii: nrclinonc.2018.
    PubMed    


  40. ROMERO D
    Breast cancer: Recurrent fusions in endocrine-resistant disease.
    Nat Rev Clin Oncol. 2018 Feb 6. pii: nrclinonc.2018.
    PubMed    


    January 2018
  41. VAZ-LUIS I, Partridge AH
    Exogenous reproductive hormone use in breast cancer survivors and previvors.
    Nat Rev Clin Oncol. 2018 Jan 23. pii: nrclinonc.2017.
    PubMed     Abstract available


    December 2017
  42. PEREZ-GARCIA J, Cortes J
    Breast cancer in 2017: Spurring science, marking progress, and influencing history.
    Nat Rev Clin Oncol. 2017 Dec 12. pii: nrclinonc.2017.
    PubMed    


    October 2017
  43. SIDAWAY P
    Breast Cancer: Abemaciclib effective in combination with aromatase inhibition.
    Nat Rev Clin Oncol. 2017 Oct 17. doi: 10.1038/nrclinonc.2017.
    PubMed    


  44. SIDAWAY P
    Breast cancer: LAG3 expression indicates favourable outcomes.
    Nat Rev Clin Oncol. 2017 Oct 10. doi: 10.1038/nrclinonc.2017.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: